Kyverna Therapeutics

kyvernatx.com

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing CAR T-cell therapies for autoimmune diseases. Their lead candidate, KYV-101, is advancing through clinical trials targeting conditions such as multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. By leveraging the success of CAR T-cell therapies in hematological malignancies, Kyverna aims to provide sustained treatment-free remission for patients with B cell-driven autoimmune diseases. The company is actively conducting clinical trials across the globe, positioning itself as a leader in the innovative treatment of autoimmune disorders.